Month: July 2022
-
Infographic – Fewer in US See Covid-19 Threat
The percentage of Americans viewing Covid-19 as a major threat to public health is declining, with a majority now saying the disease is a minor or no threat at all.
-
Biotech Start-Up Demonstrates Cancer Therapy, Raises $6.4M
A new biotechnology company demonstrated in lab mice its therapy for glioblastoma, an aggressive brain cancer, that overcomes limitations of current treatments.
-
Women’s Health Companies Partner on New Contraceptive
Two companies working in women’s reproductive health are developing a new non-hormonal contraceptive that works in cervical mucous membranes.
-
Biotechs Discover Antimicrobial Peptide for Food Safety
Two biotechnology companies say they discovered a peptide molecule with antimicrobial properties for faster identification and containment of food contamination outbreaks.
-
Small Biz Grant Funds Non-Viral Gene Editing Delivery
National Institutes of Health is financing a delivery method for gene-editing therapies to blood-forming stem cells with natural lipid bubbles instead of viruses.
-
Ginkgo Acquires Biomaterials Maker as Industry Consolidates
A developer of synthetic biology tools and components is acquiring a biological materials developer for its automation assets as the biotechnology industry consolidates.
-
Infographic – Digital Health Keeps Clicking in 2022
While venture capital funding for digital health start-ups worldwide is down compared to last year, the pace so far in 2022 remains on an historically strong track.
-
AI System Shown to Provide Early Sepsis Warnings
A system using machine learning algorithms is shown to provide early warnings about sepsis developing in hospitalized patients, reducing injury and death.
-
Trial Okayed for Engineered Cell Cancer Therapy
A clinical trial is set to begin testing engineered immune-system cells designed to precisely target and infiltrate cancerous tumors without other potentially toxic proteins.
-
Trial Shows Oral Covid-19 Vaccine Produces Antibodies
A clinical trial shows a Covid-19 vaccine taken as a tablet produces protective antibodies in nasal membranes that in some cases last for up to a year.